
M-Life™ is a life sciences company dedicated to reinventing drug discovery through the use of AI and advanced pattern recognition. They combine AI, molecular transcription, data fusion, and expert knowledge to create viable solutions for curing diseases and addressing challenges in oncology, Alzheimer's, analgesics, and antibiotics. Their proprietary platforms, P2L™ (Pattern-to-Lead) and MiST™ (Molecular in Silico Tomography), are used for repurposing existing drugs, selecting high-value molecules, and designing novel molecules. The company has 14 programs, with oncology Multi-Targeting Agents (MTAs) currently in preclinical testing. The team comprises innovators with extensive experience in drug discovery, bioinformatics, AI, and chemistry, holding over 400 patents and numerous publications.

M-Life™ is a life sciences company dedicated to reinventing drug discovery through the use of AI and advanced pattern recognition. They combine AI, molecular transcription, data fusion, and expert knowledge to create viable solutions for curing diseases and addressing challenges in oncology, Alzheimer's, analgesics, and antibiotics. Their proprietary platforms, P2L™ (Pattern-to-Lead) and MiST™ (Molecular in Silico Tomography), are used for repurposing existing drugs, selecting high-value molecules, and designing novel molecules. The company has 14 programs, with oncology Multi-Targeting Agents (MTAs) currently in preclinical testing. The team comprises innovators with extensive experience in drug discovery, bioinformatics, AI, and chemistry, holding over 400 patents and numerous publications.